coumarin and tegafur
coumarin has been researched along with tegafur in 4 studies
Research
Studies (4)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Brodsky, JL; Chiang, A; Chung, WJ; Denny, RA; Goeckeler-Fried, JL; Havasi, V; Hong, JS; Keeton, AB; Mazur, M; Piazza, GA; Plyler, ZE; Rasmussen, L; Rowe, SM; Sorscher, EJ; Weissman, AM; White, EL | 1 |
| Kaniwa, N; Murayama, N; Nakajima, Y; Ohno, Y; Ozawa, S; Sai, K; Sawada , J | 1 |
| Ariyoshi, N; Daigo, S; Fujieda, M; Ikeda, K; Kamataki, T; Koizumi, W; Nagayama, S; Nishioka, Y; Saigenji, K; Takahashi, Y; Tanabe, S; Yamazaki, H | 1 |
| Chiba, M; Ishii, Y; Yamada, H; Yamamiya, I; Yoshisue, K | 1 |
Other Studies
4 other study(ies) available for coumarin and tegafur
| Article | Year |
|---|---|
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
Topics: Alleles; Benzoates; Cells, Cultured; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Endoplasmic Reticulum; Furans; Gene Deletion; HEK293 Cells; HeLa Cells; High-Throughput Screening Assays; Humans; Hydroxamic Acids; Microscopy, Fluorescence; Protein Folding; Protein Structure, Tertiary; Pyrazoles; RNA, Messenger; Small Molecule Libraries; Ubiquitination; Vorinostat | 2016 |
Expression of CYP2A6 in tumor cells augments cellular sensitivity to tegafur.
Topics: Antimetabolites, Antineoplastic; Aryl Hydrocarbon Hydroxylases; Cell Division; Colonic Neoplasms; Coumarins; Cytochrome P-450 CYP2A6; Cytochrome P-450 Enzyme System; Fluorouracil; Gene Expression; Humans; Hydroxylation; Microsomes; Mixed Function Oxygenases; Tegafur; Transfection; Tumor Cells, Cultured | 2001 |
A novel mutant allele of the CYP2A6 gene (CYP2A6*11 ) found in a cancer patient who showed poor metabolic phenotype towards tegafur.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Coumarins; Cytochrome P-450 CYP2A6; DNA Primers; DNA, Neoplasm; Drug Combinations; Escherichia coli; Genotype; Humans; Kinetics; Middle Aged; Mixed Function Oxygenases; Mutagenesis, Site-Directed; Oxonic Acid; Polymerase Chain Reaction; Polymorphism, Genetic; Pyridines; Recombinant Proteins; Stomach Neoplasms; Tegafur; Transfection | 2002 |
Effect of CYP2A6 genetic polymorphism on the metabolic conversion of tegafur to 5-fluorouracil and its enantioselectivity.
Topics: Cell Line; Coumarins; Cytochrome P-450 CYP2A6; DNA, Complementary; Escherichia coli; Fluorouracil; Humans; Microsomes, Liver; Nicotine; Polymorphism, Genetic; Sf9 Cells; Tegafur | 2014 |